Q1 · MEDICINE
Article
Author: Flattery, Amy ; Murgolo, Nicholas ; Markgraf, Carrie ; Dong, Shuzhi ; Root, Yuriko ; Mirza, Asra ; Hicks, Jacqueline D. ; Chu, Inhou ; Fischmann, Thierry ; Villafania, Artjohn ; Young, Katherine ; Sheth, Payal ; Kim, Hai-Young ; Chu, Donald ; Scapin, Giovanna ; Mandal, Mihirbaran ; Tata, Jim ; Weber, Ann E. ; Su, Jing ; Pan, Jianping ; DiNunzio, Edward ; Xiao, Li ; Wu, Jin ; Li, Guoqing ; Garlisi, Charles ; Zhang, Rumin ; Yang, Shu-Wei ; Hagmann, William K. ; Dayananth, Priya ; Mayhood, Todd W. ; Wyss, Daniel F. ; de Jesus, Reynalda Keh ; Tang, Haiqun ; Pasternak, Alexander ; Black, Todd ; Buevich, Alexei V. ; Liang, Lianzhu ; Tang, Haifeng ; Prosise, Winnie ; Therien, Alex G. ; Pan, Weidong ; Parmee, Emma R. ; Painter, Ronald ; Yang, Christine
With the emergence and rapid spreading of NDM-1 and existence of clinically relevant VIM-1 and IMP-1, discovery of pan inhibitors targeting metallo-beta-lactamases (MBLs) became critical in our battle against bacterial infection. Concurrent with our fragment and high-throughput screenings, we performed a knowledge-based search of known metallo-beta-lactamase inhibitors (MBLIs) to identify starting points for early engagement of medicinal chemistry. A class of compounds exemplified by 11, discovered earlier as B. fragilis metallo-beta-lactamase inhibitors, was selected for in silico virtual screening. From these efforts, compound 12 was identified with activity against NDM-1 only. Initial exploration on metal binding design followed by structure-guided optimization led to the discovery of a series of compounds represented by 23 with a pan MBL inhibition profile. In in vivo studies, compound 23 in combination with imipenem (IPM) robustly lowered the bacterial burden in a murine infection model and became the lead for the invention of MBLI clinical candidates.